spec sheet6 rows
Arecaidine is the carboxylic acid sitting one hydrolysis step away from arecoline, the alkaloid that makes areca nut a stimulant. Lime in a betel quid strips the methyl ester off arecoline, and the body does the same thing afterwards, so anyone chewing areca is exposed to substantial arecaidine whether or not it was in the nut to begin with. Chemically it is N-methylguvacine, which puts it in the same small family as guvacine and nipecotic acid, and that family does one interesting thing: it blocks GABA reuptake. Johnston's group reported that in Nature in 1975, and a follow-up in cat spinal cord and cerebellum confirmed that locally applied arecaidine makes GABA's inhibitory effect last longer without touching glycine. The catch is what happened when the same group gave it intravenously. Nothing. Systemic arecaidine failed to alter GABA-mediated synaptic inhibition at all, and a full gram per kilogram under the skin only marginally blunted bicuculline lethality in mice, with little or no anticonvulsant effect to speak of. It is a real transporter inhibitor that cannot reliably get where it would need to act, which is why it stayed a laboratory tool rather than becoming a drug.
- Established, reproducible inhibition of GABA reuptake in brain tissue
- Prolongs GABA-mediated inhibition of neurons when applied locally, without affecting glycine or taurine responses
- Part of the guvacine and nipecotic acid scaffold that seeded the modern GABA uptake inhibitor field
- A well-characterised marker compound for tracking areca nut exposure
- Areca nut, its only natural source, is classified by IARC as a group 1 human carcinogen, with oral and oesophageal cancer the main risk
- Systemic dosing failed to alter GABA-mediated synaptic inhibition in cats, suggesting it does not reach central targets well
- Protection against bicuculline lethality in mice was marginal and needed about 1 g/kg subcutaneously; anticonvulsant activity was little or none
- No human dosing, pharmacokinetic or safety study exists for isolated arecaidine
- Habitual areca use carries dependence, withdrawal and oral submucous fibrosis risk that arecaidine exposure comes bundled with
- The alkali in a betel quid is not a flavouring; lime hydrolyses arecoline into arecaidine inside the mouth, so the chew changes its own chemistry while it is being used.
- The same cyclic GABA analogue scaffold arecaidine belongs to, through guvacine and nipecotic acid, is what medicinal chemists later built the anticonvulsant tiagabine on.
Mechanism
A uptake inhibitor at the plasma-membrane GABA transporters, structurally a cyclic GABA analogue in the guvacine and nipecotic acid mould. Applied directly to neurons it slows clearance of GABA and prolongs GABA-mediated and beta-alanine-mediated inhibition, while leaving glycine and taurine responses alone. Unlike arecoline, the methyl ester it comes from, arecaidine is not the in areca nut; the free acid loses most of that activity. Oral absorption appears to run through the proton-coupled amino acid transporter hPAT1 in the intestinal epithelium, with a low-millimolar affinity that fits a dietary alkaloid rather than a drug.
Safetyrisks and cautions, not medical advice
Cancer risk overwhelms the pharmacology here. Areca nut, effectively the only place arecaidine occurs in quantity, is classified by IARC as a group 1 human carcinogen on its own, without added tobacco, and habitual chewing causes oral submucous fibrosis, oral and oesophageal cancer, and dependence with withdrawal. Isolated arecaidine has never had a human dosing, pharmacokinetic or safety study, so its risk apart from the quid is genuinely undefined; nothing shows the free acid carries the nut's carcinogenicity and nothing rules it out. Its only defensible use is as a laboratory reagent.
History
Isolated from Areca catechu in the nineteenth century as one of the minor nut alkaloids. Nieschulz devoted the third paper of a German pharmacology series on betel constituents to arecaidine in 1970, testing its effects on mouse behaviour. The pharmacology that made it interesting came in 1975, when Johnston, Krogsgaard-Larsen and Stephanson reported in Nature that betel nut constituents inhibit GABA uptake, and in 1977, when Lodge, Johnston, Curtis and Brand worked out in cats what that meant and did not mean in a living animal. Interest then migrated to the scaffold rather than the molecule: guvacine and nipecotic acid became the templates for a generation of GABA uptake inhibitors. Modern work on arecaidine is mostly analytical and toxicological, tracking it as an arecoline metabolite in the areca nut cancer literature.
Subjective profileweighing the evidence above
A useful piece of GABA transporter pharmacology and a genuinely bad thing to consume, for reasons that have nothing to do with its GABA activity. The source material is a group 1 human carcinogen, the systemic evidence for central effects is weak, and there is no version of taking this that makes sense outside a laboratory.
Resources
This entry is here for reference.
Research
- 1970first cited[Pharmacology of the active substances in betel. 3. Experiments with arecaidine].
- 2013most recentTransport of the areca nut alkaloid arecaidine by the human proton-coupled amino acid transport…
- 1.Betel nut constituents as inhibitors of gamma-aminobutyric acid uptake.
- 2.Effects of the Areca nut constituents arecaidine and guvacine on the action of GABA in the cat central nervous system.
- 3.Transport of the areca nut alkaloid arecaidine by the human proton-coupled amino acid transporter 1 (hPAT1).
- 4.A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse.
- 5.Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines.
- 6.[Pharmacology of the active substances in betel. 3. Experiments with arecaidine].
6 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is arecaidine what makes betel chewing feel stimulating?
Mostly not. Arecoline, the parasympathomimetic ester, drives the classic arousal, sweating and salivation. Arecaidine is what arecoline becomes once lime or the body hydrolyses it, and its own contribution is thought to run through GABA uptake inhibition rather than muscarinic activation.
If it blocks GABA reuptake, is it an anxiolytic or an anticonvulsant?
Not in practice. The uptake block is solid in tissue, but when arecaidine was given intravenously it did not change GABA-mediated inhibition in the animal at all, and very large subcutaneous doses only marginally reduced bicuculline lethality with little or no anticonvulsant effect. Getting into the brain is the problem.
Is areca nut safe to chew if the tobacco is left out?
No. IARC classifies areca nut itself, without added tobacco, as a group 1 human carcinogen. Removing tobacco lowers the total risk but does not make the practice safe, and oral submucous fibrosis is specifically an areca effect.
Adverse effects
- Areca nut, its only natural source, is classified by IARC as a group 1 human carcinogen, with oral and oesophageal cancer the main risk
- Systemic dosing failed to alter GABA-mediated synaptic inhibition in cats, suggesting it does not reach central targets well
- Protection against bicuculline lethality in mice was marginal and needed about 1 g/kg subcutaneously; anticonvulsant activity was little or none
- No human dosing, pharmacokinetic or safety study exists for isolated arecaidine
- Habitual areca use carries dependence, withdrawal and oral submucous fibrosis risk that arecaidine exposure comes bundled with